BioMarin Pharmaceutical Inc. (FRA:BM8)

BioMarin Pharmaceutical Statistics

Total Valuation

FRA:BM8 has a market cap or net worth of EUR 9.09 billion. The enterprise value is 8.34 billion.

Market Cap	9.09B
Enterprise Value	8.34B

Important Dates

The next estimated earnings date is Friday, February 20, 2026.

Earnings Date	Feb 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	192.11M
Shares Outstanding	n/a
Shares Change (YoY)	+2.10%
Shares Change (QoQ)	-2.57%
Owned by Insiders (%)	0.78%
Owned by Institutions (%)	96.13%
Float	190.44M

Valuation Ratios

The trailing PE ratio is 20.50 and the forward PE ratio is 11.49.

PE Ratio	20.50
Forward PE	11.49
PS Ratio	3.45
PB Ratio	1.76
P/TBV Ratio	1.90
P/FCF Ratio	12.82
P/OCF Ratio	11.67
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.00, with an EV/FCF ratio of 11.76.

EV / Earnings	18.81
EV / Sales	3.13
EV / EBITDA	12.00
EV / EBIT	13.63
EV / FCF	11.76

Financial Position

The company has a current ratio of 4.83, with a Debt / Equity ratio of 0.10.

Current Ratio	4.83
Quick Ratio	2.84
Debt / Equity	0.10
Debt / EBITDA	0.75
Debt / FCF	0.73
Interest Coverage	66.49

Financial Efficiency

Return on equity (ROE) is 9.07% and return on invested capital (ROIC) is 7.01%.

Return on Equity (ROE)	9.07%
Return on Assets (ROA)	6.15%
Return on Invested Capital (ROIC)	7.01%
Return on Capital Employed (ROCE)	10.44%
Revenue Per Employee	867,440
Profits Per Employee	145,905
Employee Count	3,040
Asset Turnover	0.43
Inventory Turnover	0.45

Taxes

In the past 12 months, FRA:BM8 has paid 135.39 million in taxes.

Income Tax	135.39M
Effective Tax Rate	23.39%

Stock Price Statistics

The stock price has decreased by -22.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-22.72%
50-Day Moving Average	46.13
200-Day Moving Average	51.69
Relative Strength Index (RSI)	55.32
Average Volume (20 Days)	25

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.40

Income Statement

In the last 12 months, FRA:BM8 had revenue of EUR 2.64 billion and earned 443.55 million in profits. Earnings per share was 2.28.

Revenue	2.64B
Gross Profit	2.14B
Operating Income	606.26M
Pretax Income	578.94M
Net Income	443.55M
EBITDA	676.77M
EBIT	606.26M
Earnings Per Share (EPS)	2.28

Balance Sheet

The company has 1.26 billion in cash and 514.99 million in debt, giving a net cash position of 744.57 million.

Cash & Cash Equivalents	1.26B
Total Debt	514.99M
Net Cash	744.57M
Net Cash Per Share	n/a
Equity (Book Value)	5.16B
Book Value Per Share	26.87
Working Capital	2.60B

Cash Flow

In the last 12 months, operating cash flow was 778.98 million and capital expenditures -69.76 million, giving a free cash flow of 709.23 million.

Operating Cash Flow	778.98M
Capital Expenditures	-69.76M
Free Cash Flow	709.23M
FCF Per Share	n/a

Margins

Gross margin is 81.32%, with operating and profit margins of 22.99% and 16.82%.

Gross Margin	81.32%
Operating Margin	22.99%
Pretax Margin	21.95%
Profit Margin	16.82%
EBITDA Margin	25.66%
EBIT Margin	22.99%
FCF Margin	26.89%

Dividends & Yields

FRA:BM8 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.10%
Shareholder Yield	-2.10%
Earnings Yield	4.88%
FCF Yield	7.80%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:BM8 has an Altman Z-Score of 5.84 and a Piotroski F-Score of 7.

Altman Z-Score	5.84
Piotroski F-Score	7